Connor Clark & Lunn Investment Management Ltd. Sells 10,704 Shares of Charles River Laboratories International, Inc. $CRL

Connor Clark & Lunn Investment Management Ltd. reduced its holdings in Charles River Laboratories International, Inc. (NYSE:CRL) by 5.6% during the 3rd quarter, Holdings Channel reports. The institutional investor owned 180,564 shares of the medical research company’s stock after selling 10,704 shares during the quarter. Connor Clark & Lunn Investment Management Ltd.’s holdings in Charles River Laboratories International were worth $28,251,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Neo Ivy Capital Management bought a new position in shares of Charles River Laboratories International in the 2nd quarter valued at about $29,000. Rothschild Investment LLC raised its holdings in Charles River Laboratories International by 82.4% during the third quarter. Rothschild Investment LLC now owns 186 shares of the medical research company’s stock worth $29,000 after acquiring an additional 84 shares in the last quarter. Atlantic Union Bankshares Corp acquired a new position in Charles River Laboratories International during the third quarter valued at approximately $31,000. Geneos Wealth Management Inc. boosted its position in Charles River Laboratories International by 98.0% during the second quarter. Geneos Wealth Management Inc. now owns 293 shares of the medical research company’s stock valued at $44,000 after purchasing an additional 145 shares during the last quarter. Finally, Allworth Financial LP grew its stake in Charles River Laboratories International by 172.7% in the second quarter. Allworth Financial LP now owns 300 shares of the medical research company’s stock valued at $45,000 after purchasing an additional 190 shares in the last quarter. 98.91% of the stock is owned by institutional investors.

Charles River Laboratories International Stock Performance

Shares of NYSE CRL opened at $152.22 on Friday. The company has a current ratio of 1.29, a quick ratio of 1.02 and a debt-to-equity ratio of 0.67. The company has a market capitalization of $7.49 billion, a P/E ratio of -51.43, a P/E/G ratio of 2.89 and a beta of 1.64. Charles River Laboratories International, Inc. has a 12 month low of $91.86 and a 12 month high of $228.88. The stock has a 50 day moving average of $192.53 and a 200-day moving average of $180.94.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings results on Wednesday, February 18th. The medical research company reported $2.39 earnings per share for the quarter, beating analysts’ consensus estimates of $2.33 by $0.06. Charles River Laboratories International had a positive return on equity of 15.60% and a negative net margin of 3.59%.The business had revenue of $994.23 million for the quarter, compared to analysts’ expectations of $986.98 million. During the same quarter in the prior year, the business earned $2.66 EPS. The firm’s revenue for the quarter was down .8% on a year-over-year basis. Charles River Laboratories International has set its FY 2026 guidance at 10.700-11.200 EPS. As a group, equities research analysts predict that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

Analyst Ratings Changes

CRL has been the topic of several recent analyst reports. Robert W. Baird set a $193.00 price target on Charles River Laboratories International in a research report on Thursday, February 19th. Citigroup raised their target price on shares of Charles River Laboratories International from $200.00 to $265.00 and gave the company a “buy” rating in a research note on Friday, January 16th. Argus set a $200.00 target price on shares of Charles River Laboratories International in a report on Monday, November 17th. Morgan Stanley set a $185.00 price target on shares of Charles River Laboratories International in a research report on Monday, December 1st. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Charles River Laboratories International from $165.00 to $190.00 and gave the company a “neutral” rating in a research report on Monday, December 15th. Ten investment analysts have rated the stock with a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $203.57.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.